Provided by Tiger Fintech (Singapore) Pte. Ltd.

AIM VACCINE

4.100
-0.930-18.49%
Volume:9.82M
Turnover:41.38M
Market Cap:5.03B
PE:-3.57
High:4.780
Open:4.780
Low:4.020
Close:5.030
Loading ...

BUZZ-China's AIM jumps on vaccine's clinical trial application in US

Reuters
·
05 Feb

AIM Vaccine For Tetanus Gets NMPA's Nod; Shares Rise 5%

MT Newswires Live
·
20 Dec 2024

AIM Vaccine Has Obtained Clinical Approval for Two Heavyweight Products, Creating New Growth Points for Performance

THOMSON REUTERS
·
20 Dec 2024

BRIEF-AIM Vaccine Says Second Generation Of Absorbed Tetanus Vaccine Obtained Clinical Trial Approval

Reuters
·
19 Dec 2024

BRIEF-AIM Vaccine Says Suspension Culture Influenza Vaccine (MDCK Cells) Got Clinical Trial Approval

Reuters
·
19 Dec 2024

AIM Vaccine - Second Generation of Highly-Effective Absorbed Tetanus Vaccine Obtained Clinical Trial Approval From Nmpa

THOMSON REUTERS
·
19 Dec 2024

AIM Vaccine Co - Suspension Culture Influenza Vaccine (Mdck Cells) Got Clinical Trial Approval From China's Nmpa

THOMSON REUTERS
·
19 Dec 2024

the Global Leader in Rabies Vaccines, the Serum-Free Iterative Rabies Vaccine of AIM Vaccine Has Submitted a Pre-Application for Marketing Registration

THOMSON REUTERS
·
18 Nov 2024

Here's Why AIM Vaccine (HKG:6660) Can Afford Some Debt

Simply Wall St.
·
15 Nov 2024

AIM Vaccine Submits Application for Clinical Trial of Rabies Vaccine to Chinese Regulator

MT Newswires Live
·
08 Nov 2024

Application for Clinical Trial of AIM Vaccine’s Human Diploid Rabies Vaccine

THOMSON REUTERS
·
08 Nov 2024

AIM Vaccine Gets Marketing Approval from China's NMPA After Phase III Trials Completion

MT Newswires Live
·
01 Nov 2024

AIM Vaccine’s 13-Valent Pneumonia Conjugate Vaccine Obtained Production License

THOMSON REUTERS
·
01 Nov 2024

BRIEF-AIM Vaccine Says Unit Obtained Requisite Drug Production License From NMPA

Reuters
·
01 Nov 2024

AIM Vaccine - Unit Obtained Requisite Drug Production License From Nmpa for Manufacturing 13-Valent Pneumonia Conjugate Vaccine

THOMSON REUTERS
·
01 Nov 2024

AIM Vaccine Unit's RSV Drug Approved by NMPA for Clinical Trials

MT Newswires Live
·
30 Oct 2024